1-20 of 286
ixazomib
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Up-front ixazomib in older patients with myeloma

Free
Jean-Luc Harousseau, Mohamad Mohty
Journal: Blood
Blood (2021) 137 (26): 3584–3586.
https://doi.org/10.1182/blood.2021011262
Published: 2021
Journal Articles

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Free
Clinical Trials & Observations
Thierry Facon, Christopher P. Venner, Nizar J. Bahlis, Fritz Offner, Darrell J. White, Lionel Karlin, Lotfi Benboubker, Sophie Rigaudeau, Philippe Rodon, Eric Voog, Sung-Soo Yoon, Kenshi Suzuki, Hirohiko Shibayama, Xiaoquan Zhang, Philip Twumasi-Ankrah, Godwin Yung, Robert M. Rifkin, Philippe Moreau, Sagar Lonial, Shaji K. Kumar, Paul G. Richardson, S. Vincent Rajkumar
Journal: Blood
Blood (2021) 137 (26): 3616–3628.
https://doi.org/10.1182/blood.2020008787
Published: 2021
Includes: Supplemental data
Journal Articles

Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5):597-605.

Free
Journal: Blood
Blood (2020) 135 (13): 1071.
https://doi.org/10.1182/blood.2020005086
Published: 2020
Journal Articles

Cost Effectiveness of Novel Agents in the Treatment of Multiple Myeloma: A Systematic Review

Free
Sarah Perry, MD MSc, Sylvia McCulloch, MD MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 4738.
https://doi.org/10.1182/blood-2019-125454
Published: 2019
Journal Articles

High Rates of Venous and Arterial Thrombotic Events in POEMS Patients: Results from the UK-Based POEMS Registry, Highlighting the Need for Therapeutic Guidelines

Free
Zara Sayar, MD FRCPath, MRCP, Anna Weatherill, Stephen Keddie, Jonathan Sive, MD, Michael P Lunn, Mari Thomas, Shirley D'Sa
Journal: Blood
Blood (2019) 134 (Supplement_1): 714.
https://doi.org/10.1182/blood-2019-125639
Published: 2019
Journal Articles

Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

Free
Prashant Kapoor, MD, Morie A. Gertz, MD, Betsy Laplant, MS, Gabriella C Malave, BA, Eric Wolfe, Eli Muchtar, MD, Mustaqeem A. Siddiqui, MDMBA, Wilson I Gonsalves, MD, Angie R. Emanuel, Taxiarchis Kourelis, MD, Rahma Warsame, MD, David Dingli, MD PhD, Francis K. Buadi, MB, CHB, Suzanne R. Hayman, MD, Nelson Leung, MD, Yi L. Hwa, APRN, CNP, DNP, Miriam A. Hobbs, APRN, CNP, DNP, Amie Fonder, PA-C, MS, Angela Dispenzieri, MD, Martha Q. Lacy, MD, S. Vincent Rajkumar, MD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 864.
https://doi.org/10.1182/blood-2019-131476
Published: 2019
Journal Articles

A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404

Free
Jonathon B. Cohen, MDMS, Craig A. Portell, MD, Mehdi Hamadani, MD, Opeyemi Jegede, PhD, Catherine Diefenbach, MD, Kevin A. David, MD, Christopher D. Fletcher, MD, Daniel J. Landsburg, MD, Brad S. Kahl, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1541.
https://doi.org/10.1182/blood-2019-127494
Published: 2019
Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Free
Claudia A.M. Stege, MD, Kazem Nasserinejad, Ellen van der Spek, MD PhD, Roel J.W. Van Kampen, MD PhD, Maaike Sohne, MD, Noortje Thielen, MD PhD, Yavuz Bilgin, MD PhD, Esther G.M. De Waal, MD, Inge Ludwig, MD MSc, Maria B.L. Leijs, MD, Alain Kentos, MD, Gert Jan Timmers, MD PhD, Koen de Heer, MD, Matthijs Westerman, MD, Marie Christiane Vekemans, Nazik Durdu-Rayman, MD, Nicole C.H.P. van der Burg-de Graauw, MD, Niels W. C. J. Van De Donk, MD PhD, Pieter Sonneveld, Saskia K. Klein, MD PhD, Mark-David Levin, MD PhD, Sonja Zweegman, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 695.
https://doi.org/10.1182/blood-2019-121694
Published: 2019
Journal Articles

Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial

Free
Ravi Vij, MBBS, Thomas G. Martin, III, MD, Nitya Nathwani, MD, Mark A. Fiala, BS, Feng Gao, PhD, Abhinav Deol, MD, Francis K. Buadi, MB, CHB, Jonathan L. Kaufman, MD, Craig C Hofmeister, MDMPH, Tara K. Gregory, MD, Jesus G. Berdeja, MD, Ajai Chari, MD, Ashley E. Rosko, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 602.
https://doi.org/10.1182/blood-2019-130644
Published: 2019
Journal Articles

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Free
Mark Bustoros, MD, Omar Nadeem, MD, Adam S Sperling, MD PhD, Giada Bianchi, MD, Lily Ardente, BS, Robert A. Redd, MS, Julia Prescott, NP, Erin Frey, RN, Kathleen Guimond, RN, Rachel Styles, BS, Kalvis Hornburg, BA, Alexandra Savell, BS, Nang Kham Su, BA, Govind Bindra, BA, Cody J Boehner, BS, Kaitlen Reyes, DNP, Houry Leblebjian, PharmD, Diane Warren, Nikhil C. Munshi, MD, Jacob P. Laubach, MD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Irene M. Ghobrial, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 580.
https://doi.org/10.1182/blood-2019-128519
Published: 2019
Journal Articles

Pharmacological Perturbation of the Immunoproteasome in Hematologic Neoplasias: Therapeutic Implications

Free
Sondra L. Downey-Kopyscinski, PhD, Ricardo De Matos Simoes, PhD, Megan Bariteau, BSc, Minasri L. Borah, Sam Bender, Janaka Foneska, Jennifer Roth, Richard Groen, Gina Walter, Manja Friese-Hamim, Samantha M. Goodstal, Michael Sanderson, Constantine S. Mitsiades, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1291.
https://doi.org/10.1182/blood-2019-130356
Published: 2019
Journal Articles

RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia

Free
Christina A. Snider, BA, Kevin Fung, Francesca Gould, Vera Adema, PhD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, Hassan Awada, MD, Milo Co, Teodora Kuzmanovic, BA, Bhumika J. Patel, MD, Aaron T. Gerds, MD MS, Sudipto Mukherjee, MD PhD MPH, Aziz Nazha, MD, Hetty E. Carraway, MD MBA, Tomas Radivoyevitch, PhD, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD, Mikkael A. Sekeres, MD MS, Anjali S. Advani, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2696.
https://doi.org/10.1182/blood-2019-126311
Published: 2019
Journal Articles

Effect and Safety of Ixazomib Plus Dexamethasone (ID) in Patients with Waldenstrom's Macroglobulinemia (WM): Real-World Evidences from a Single Center in China

Free
Jiadai Xu, Zheng Wei, MD, Jing Li, MD, Jingli Zhuang, Lili Ji, Peng Liu, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5265.
https://doi.org/10.1182/blood-2019-128816
Published: 2019
Journal Articles

Targeting MDM2 and XIAP By Idasanutlin in Diffuse Large B-Cell Lymphoma

Free
Juan J. Gu, MD PhD, Samuel J. Thompson, Cory Mavis, MSc, Matthew J. Barth, MD, Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5301.
https://doi.org/10.1182/blood-2019-129009
Published: 2019
Journal Articles

Bortezomib Overcomes Poor Prognosis Conferred By High Sictp in Untreated Plasma Cell Disorders

Free
Akira Honda, MD PhD, Yu Oyama, MD, Kazuhiro Toyama, MD PhD, Mineo Kurokawa, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5492.
https://doi.org/10.1182/blood-2019-129324
Published: 2019
Journal Articles

In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma

Free
Harish Kumar, PhD, Ujjal Kumar Mukherjee, PhD, Li Chen, PhD, Amit Kumar Mitra, PhD MSc, BSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 5543.
https://doi.org/10.1182/blood-2019-131923
Published: 2019
Journal Articles

Real-World Data on Safety and Efficacy of Venetoclax-Based Regimens in Relapsed/Refractory t[11;14] Multiple Myeloma

Free
Diana Basali, MD, Rajshekhar Chakraborty, MD, Lisa Rybicki, MS, Nathaniel Rosko, PharmD, Janice Reed, RN, Mary Ann Karam, RN, Kristen Schlueter, RN, Hayley Dysert, Beth M. Faiman, PhDCNP, Kimberly Hamilton, APRN/PA, Matt Kalaycio, MD, Jason Valent, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5566.
https://doi.org/10.1182/blood-2019-129002
Published: 2019
Journal Articles

Advancements in Treatment for Newly Diagnosed Frail and Elderly Myeloma Patients: A Systematic Review

Free
Syed Maaz Abdullah, MBBS, Tariq Iqtidar Sadiq Syed, MD, Muhammad Salman Faisal, MD MBBS, Awais Ijaz, MD, Syeda Sabeeka Batool, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Muhammad Abdullah Yousaf, MBBS, MD, Saif Ur Rehman, MBBS, MD, Maaz Ahmed Yusufi, MD, Sravanthi Kotapati, MBBS, Maimoona Khan, MBBS, Asma Waheed, MBBS, Khadija Zia Zaidi, MBBS, Sikander Abdullah, MBBS, Faiz Anwer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5589.
https://doi.org/10.1182/blood-2019-128892
Published: 2019
Journal Articles

The Efficacy and Safety Profile of Ixazomib-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma in Routine Clinical Practice: Real World Data from a Multi-Center Study in China

Free
Jing Li, MD, Li Bao, Zhong-jun Xia, MD, Kaiyang Ding, Bingzong Li, MD PhD, Bing Chen, Zhengzheng Fu, Sili Wang, Wenhao Zhang, MD PhD, Xin Zhou, Luoming Hua, PhD, Wei Yang, Luo Jun, Liang Wang, Tianhong Xu, Yang Yang, Weida Wang, MD, Guolin Wu, Yun Huang, Peng Liu, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5592.
https://doi.org/10.1182/blood-2019-130040
Published: 2019
Journal Articles

Retrospective Analysis of the Efficacy of Triplet Therapy, Including Lenalidomide, in Newly Diagnosed Multiple Myeloma Patients Who Obtained Responses Less Than VGPR after Rd Therapy

Free
Naoki Takezako, MD PhD, Naoya Kaneko, MD, Airi Hamano, Ph, Kenichi Ito, MD, Naohiro Sekiguchi, MD, Satoshi Noto, MD, Takanori Teshima, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5595.
https://doi.org/10.1182/blood-2019-131617
Published: 2019